Keryx Biopharmaceuticals Inc.
(KERX:NASDAQ)
Snapshot of Keryx Biopharmaceuticals Inc. (KERX)
|
OPEN
$2.35
|
PREVIOUS CLOSE
$2.30
|
|
|
DAY HIGH
$2.36
|
DAY LOW
$2.25
|
|
|
52 WEEK HIGH
09/23/09 - $3.33
|
52 WEEK LOW
03/5/09 - $0.09
|
|
|
MARKET CAP
128.2M
|
AVERAGE VOLUME 3 mo
788.7K
|
|
|
DILUTED EPS TTM
$0.23
|
SHARES OUTSTANDING
56.0M
|
|
|
KERX Does Not Pay Dividends
|
P/E TTM
9.9x
|
|
| K = Thousands M = Millions B = Billions | ||
related business week news
KERX Details
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. The company was formerly known as Lakaro Biopharmaceuticals, Inc. and changed its name to Keryx Biopharmaceuticals, Inc. in January 2000. Keryx Biopharmaceuticals, Inc. was founded in 1998 and is based in New York, New York.
KERX Top Compensated Officers
Key developments for Keryx Biopharmaceuticals Inc. (KERX)
Keryx Biopharmaceuticals Inc., Q3 2009 Earnings Call, Nov-10-2009
Keryx Biopharmaceuticals Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on November 6, 2009).
Keryx Biopharmaceuticals Inc. - Conference Presentation Calls
Stock Quotes
| Recently Viewed | |||
| KERX | $2.29 USD | -0.01 |  |
|---|---|---|---|
| RX | $21.66 USD | +0.21 |  |
| BBSI | $11.05 USD | +0.03 |  |
| STJ | $35.01 USD | +0.69 |  |
| TCB | $12.66 USD | +0.26 |  |
Market data is delayed at least 20 minutes.
KERX Competitors
| Company | Last | Change |
| Abbott Laboratories | $53.13 USD | -0.51 |
| Bristol Myers Squibb Co | $25.05 USD | +0.59 |
| Eli Lilly and Co | $36.80 USD | +0.21 |
| Genzyme Corp | $50.24 USD | +0.19 |
| GTx Inc | $3.67 USD | +0.16 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | KERX | Industry Range |
| Price/Earnings | 9.7x |
|
| Price/Sales | 5.0x |
|
| Price/Book | 3.7x |
|
| Price/Cash Flow | 11.3x |
|
| TEV/Sales | 4.3x |
|
|
KERX |
||
KERX transactions
| Type Date |
Target |
|
Private Placement
September 25, 2009 |
-- |
Companies Toolbox
Update/report
Submit private company
Upload your company video
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- Painesville, OH-Avery Dennison
- Houston, TX-Halliburton
- Houston, TX-Halliburton
- New York, NY-Duff & Phelps
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For Keryx Biopharmaceuticals Inc. (KERX) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
